title: Nivolumab for recurrent squamous-cell carcinoma of the head and neck.
abstract: Increased overall survival with nivolumab albeit only 7.5 months vs 5.1 months, and a better quality of life.
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D009364:Neoplasm Recurrence, Local; D000077594:Nivolumab; D011788:Quality of Life
chemical_list: D000911:Antibodies, Monoclonal; D000077594:Nivolumab